Food and Drug Administration, HHS.
This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.
Name of Committee: Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee.
General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.
Date and Time: The meeting will be held on March 12, 2002, from 8 a.m. to 5 p.m.
Location: CDER Advisory Committee Conference Room, Rm. 1066, 5630 Fishers Lane, Rockville, MD.
Contact Person: Thomas H. Perez or Kimberly Littleton Topper, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, by phone at 301-827-7001, or by e-mail at PerezT@cder.fda.gov or TopperK@cder.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12542. Please call the Information Line for up-to-date information on this meeting.
Agenda: The subcommittee will discuss potential conflicts of interest in pediatric oncology clinical trials, off-protocol patient access to investigational drugs, and access to investigational drugs for nonclinical studies.
Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the subcommittee. Written submissions may be made to the contact person by March 4, 2002. Oral presentations from the public will be scheduled between approximately 8:15 a.m. and 12:45 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before March 4, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.
Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Thomas H. Perez or Kimberly Littleton Topper at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).Start Signature
Dated: January 31, 2002.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 02-2950 Filed 2-6-02; 8:45 am]
BILLING CODE 4160-01-S